AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- The utility of chromogenic in situ hybridization (CISH) in detection of HER-2/neu amplification has been evaluated in breast cancer patients.
"Determining of HER-2/neu oncogene amplification has become clinically important for managing breast cancer," scientists in South Korea explained. "Fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) are currently regarded as the standard methods."
In a study conducted by E. Chang and colleagues at the Catholic University of Korea, "(CISH) was investigated as a new modification with an accurate, sensitive technique."
"From 1998 to 2002, using CISH and IHC, the amplification and protein expression of the HER-2/neu oncogene were examined using paraffin sections in 130 breast carcinomas and to determine the prognostic role of HER-2/neu for outcome after a follow-up of 24-64 months," the collaborators said. "Amplifications by CISH and overexpression by IHC were observed in 28 (22%) and 27 cases (20.8%), respectively."
"Of the 104 patients, 20 patients (19.2%) with amplification had a shorter disease-free interval (34.9 months vs. 38.0 months in controls) (p=0.372)," published data showed. "15 patients (14.4%) had a disease recurrence, but there is no significant difference between 3 patients amplifying the oncogene ...
Source: HighBeam Research, Utility of CISH in detecting HER-2/neu amplification evaluated.